Sep 03, 2025 mdma

Spotlight: Harriet de Wit: What can we learn about behavior and brain processes by studying psychoactive drugs in humans?

"her laboratory demonstrated that MDMA enhances feelings of social connectedness during interpersonal interactions, findings that have profound implications for PTSD treatment and psychotherapy."

by Michael DeMarco, PhD

Spotlight: Single Treatment With MM120 (Lysergide) in Generalized Anxiety DisorderA Randomized Clinical Trial (Robinson, et al, 2025)

In this phase 2b, multicenter, randomized, double-blind, placebo-controlled study of 4 dose levels of MM120 (a form of LSD) that included 198 adults with generalized anxiety disorder 4 was statistically significant.

04 Sep

Spotlight: Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)

"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."

03 Sep

Spotlight: Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial (McGowan, et al, 2025)

"In this trial, COMP360 psilocybin administered in a single session with psychological support was found to be generally well-tolerated and without serious risk to safety... treatment associated with rapid, sustained reduction in PTSD symptoms, improved functioning and quality of life to 12 weeks"

02 Sep

Spotlight: Brain changes associated with depression treatment: a meta-analysis

Meta-analysis of data from 302 depressed subjects yielding 87 foci across 18 experiments examining various depression treatments including pharmacology, psychotherapy, electroconvulsive therapy, psilocybin, and ketamine with brain activity measures in response to emotion tasks in the scanner.

01 Sep

Is ketamine a "psychedelic"?

Yes.

29 Aug

Spotlight: Long-term benefits of single-dose psilocybin in depressed patients with cancer (Agrawal, et al, 2025)

"These findings demonstrate robust antidepressive activity from a single 25 mg dose of psilocybin combined with psychotherapy and suggest a potentially paradigm-changing alternative to traditional antidepressants requiring further study."